Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo and its US subsidiary, Daiichi Sankyo, Inc, have commenced litigation against Mylan and its subsidiary, Matrix, in the US District Court of New Jersey for infringement of the company's US patent covering olmesartan medoxomil, one of the active ingredients in Daiichi Sankyo's antihypertensive drug, Azor.
Subscribe to our email newsletter
Matrix has filed an abbreviated new drug application with the FDA seeking to market a generic version of Azor. Daiichi Sankyo and Daiichi Sankyo, Inc intend to vigorously defend the patent, which expires in April 2016 in the US.
Olmesartan medoxomil is an angiotensin II receptor antagonist that Daiichi Sankyo independently developed, and is marketed in over 50 countries as an antihypertensive drug which suppresses vasoconstriction by affecting the rennin-angiotensin system to control blood pressure.